Compile Data Set for Download or QSAR
Report error Found 2685 Enz. Inhib. hit(s) with Target = 'Histone acetyltransferase KAT6A'
TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730926(US20250122183, Example 139)
Affinity DataKi:  0.100nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730902(US20250122183, Example 115)
Affinity DataKi:  0.100nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730882(US20250122183, Example 095)
Affinity DataKi:  0.100nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731005(US20250122183, Example 218)
Affinity DataKi:  0.100nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730869(US20250122183, Example 082)
Affinity DataKi:  0.100nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730964(N-{6-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-5-met...)
Affinity DataKi:  0.100nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730848(US20250122183, Example 061)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730871(US20250122183, Example 084)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730851(US20250122183, Example 064)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730906(US20250122183, Example 119)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731006(US20250122183, Example 219)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730804(US20250122183, Example 016)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731004(US20250122183, Example 217)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731037(US20250122183, Example 250)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731003(US20250122183, Example 216)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731031(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  0.200nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731036(US20250122183, Example 249)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731013(US20250122183, Example 226)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM662989(Synthesis of N-(5-((1H-pyrazol-1-yl)methyl)-3,4-di...)
Affinity DataIC50: 0.300nMAssay Description:a. The prepared enzyme solution was added to a 384-well plate at 3 μL/well, and 3 μL of 1× assay buffer was added to each well in columns 23 and 24 (...More data for this Ligand-Target Pair
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731052(US20250122183, Example 265)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM739500(N-(5-((1H-pyrazol-1-yl)methyl)-3,4-dihydro-2H-chro...)
Affinity DataIC50: 0.300nMAssay Description:a. The prepared enzyme solution was added to a 384-well plate at 3 μL/well, and 3 μL of 1× assay buffer was added to each well in columns 23 and 24 (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580758(US11492346, Example 103)
Affinity DataKi:  0.300nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730909(US20250122183, Example 122)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730972(N-{6-[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-met...)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730965(N-{6-[(5-cyclopropyl-1 H-pyrazol-3-yl)amino]-5-met...)
Affinity DataKi:  0.300nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580691(US11492346, Example 31)
Affinity DataKi:  0.320nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580784(US11492346, Example 129)
Affinity DataKi:  0.330nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580680(US11492346, Example 20)
Affinity DataKi:  0.340nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580669(US11492346, Example 9 | US11492346, Example 90 | U...)
Affinity DataKi:  0.350nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580675(US11492346, Example 15)
Affinity DataKi:  0.350nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580701(US11492346, Example 41)
Affinity DataKi:  0.360nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580669(US11492346, Example 9 | US11492346, Example 90 | U...)
Affinity DataKi:  0.380nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent
PDB3D3D Structure (crystal)
TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580678(US11492346, Example 18)
Affinity DataKi:  0.380nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM739493(N-(5-((1H-pyrazol-1-yl)methyl)-3,4-dihydro-2H-chro...)
Affinity DataIC50: 0.400nMAssay Description:a. The prepared enzyme solution was added to a 384-well plate at 3 μL/well, and 3 μL of 1× assay buffer was added to each well in columns 23 and 24 (...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
TBA
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731002(US20250122183, Example 215)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730821(US20250122183, Example 034)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730962(N-{6[(3-cyclopropyl-1 H-pyrazol-5-yl)amino]-5-meth...)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731023(US20250122183, Example 236)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580710(US11492346, Example 50)
Affinity DataKi:  0.400nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730990(US20250122183, Example 203)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731007(US20250122183, Example 220)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM580774(US11492346, Example 119 | US20250122183, Example 0...)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731010(US20250122183, Example 223)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM730957(US20250122183, Example 170)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A(Human)
Pfizer

US Patent
LigandPNGBDBM731014(US20250122183, Example 227)
Affinity DataKi:  0.400nMAssay Description:1. Final reaction conditions are 2.5 nM KAT6A Full length enzyme, 25 μM AcCoA,2 μM H3 1-21 peptide, in a 20 μL reaction volume.2. Add 200 nL of dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
8/18/2025
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580661(US11492346, Example 1)
Affinity DataKi:  0.430nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580750(US11492346, Example 92)
Affinity DataKi:  0.450nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580710(US11492346, Example 50)
Affinity DataKi:  0.460nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580684(US11492346, Example 24)
Affinity DataKi:  0.460nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent

TargetHistone acetyltransferase KAT6A [507-778](Human)
Pfizer

US Patent
LigandPNGBDBM580669(US11492346, Example 9 | US11492346, Example 90 | U...)
Affinity DataKi:  0.460nMAssay Description:A. Compound preparation 1. Prepare 10 mM stock solutions in 100% DMSO from solid material 2. Serial dilute 10 mM, 1 mM or 0.1 mM compound stocks 3-fo...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/20/2023
Entry Details
US Patent
PDB3D3D Structure (crystal)
Displayed 1 to 50 (of 2685 total ) | Next | Last >>
Jump to: